Expertise in
5
conditions

Lu-gui Y. Qiu

State Key Laboratory Of Blood Sciences, Chinese Academy Of Medical Sciences And Peking Union Medical College, 
Tianjin, CN 
Expertise in
5
conditions
State Key Laboratory Of Blood Sciences, Chinese Academy Of Medical Sciences And Peking Union Medical College, 
Tianjin, CN 
OverviewLocationsClinical Research

Overview

Lu-gui Qiu practices in Tianjin, China. Qiu is highly rated in 5 conditions, according to our data. Their top areas of expertise are Multiple Myeloma, Waldenstrom Macroglobulinemia, Small Lymphocytic Lymphoma (SLL), Chronic Lymphocytic Leukemia (CLL), and Bone Marrow Transplant.

Their clinical research consists of co-authoring 97 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years.

Locations

State Key Laboratory Of Blood Sciences, Chinese Academy Of Medical Sciences And Peking Union Medical College, Tianjin, China
Other Locations
Beijing, China
State Key Laboratory Of Experimental Hematology, Chinese Academy Of Medical Sciences And Peking Union Medical College, No. 288 Nanjing Road, 3000241, Xiaobailou, 300024, China
Langfang, 065201, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Multicenter, Randomized, Double-blind, Parallel-controlled Trial to Compare the Bioequivalence and Safety of the Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody Injection (JHL1101) and Rituximab Injection in CD20 Positive B Cell Lymphoma Patients
A Multicenter, Randomized, Double-blind, Parallel-controlled Trial to Compare the Bioequivalence and Safety of the Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody Injection (JHL1101) and Rituximab Injection in CD20 Positive B Cell Lymphoma Patients
Enrollment Status: Terminated
Publish Date: January 09, 2020
Intervention Type: Biological
Study Phase: Phase 1

97 Total Publications

Talquetamab, a GPRC5D×CD3 bispecific antibody, in Chinese patients with relapsed/refractory multiple myeloma: efficacy and safety from the phase 1/2 MonumenTAL-1 study.
Talquetamab, a GPRC5D×CD3 bispecific antibody, in Chinese patients with relapsed/refractory multiple myeloma: efficacy and safety from the phase 1/2 MonumenTAL-1 study.
Journal: Haematologica
Published: May 01, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Qiu's expertise for a condition
ConditionClose
      View All 14 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile